STAT inhibition in the treatment of cancer: Transcription factors as targets for molecular therapy

Current Cancer Therapy Reviews

Volumn 2, Issue 1, 2006, Pages 57-65

  Frank, David A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Molecular oncology; Protein phosphorylation; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; CUCURBITACIN I; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; FLUDARABINE; IMATINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOTOSENSITIZING AGENT; PROTEIN SH2; PROTEIN TYROSINE KINASE INHIBITOR; ROSCOVITINE; STAT PROTEIN; TRANSCRIPTION FACTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DNA BINDING; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NONVIRAL GENE THERAPY; OVARY CANCER; PANCREAS CANCER; PATHOGENESIS; PHENOTYPE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN LYMPHOMA; T CELL LYMPHOMA; TUMOR CELL;

EID: 33746130395     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406775471803     Document Type: Review

References (59)

1. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400: 468-472.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996; 2: 561-566.
3. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on large series of patients and cell lines. Leukemia 1997; 11: 1605-1609.
6. Setoyama C, Frunzio R, Liau G, Mudryj M, de Crombrugghe B. Transcriptional activation encoded by the v-fos gene. Proc Natl Acad Sci U S A 1986; 83: 3213-3217.
7. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
8. Darnell JE, Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
9. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996; 84: 331-334.
10. Nelson EA, Walker SR, Alvarez JA, Frank DA. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J Biol Chem 2004; 279: 54724-54730.
11. Alvarez JV, Frank DA. Genome-wide analysis of STAT target genes: Elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol Therapy 2004; 3: 1045-50.
12. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000; 19: 2496-2504.
13. Frank DA. STAT signaling in cancer: Insights into pathogenesis and treatment strategies. Cancer Treat Res 2003; 115: 267-291.
14. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999; 59: 5059-63.
15. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Statl gene results in compromised innate immunity to viral disease. Cell 1996; 84: 443-450.
16. Meraz MA, White JM, Sheehan KCF, et al. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity of the JAK-STAT signaling pathway. Cell 1996; 84: 431-442.
17. Liu X, Robinson GW, Wagner K-U, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-186.
18. Socolovsky M, Fallon AE, Wang S, Brugnara, C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/-mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999; 98: 181-91.
19. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-850.
20. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc Natl Acad Sci 1997; 94: 3801-3804.
21. Akira S. Roles of STAT3 defined by tissue-specific gene targeting. Oncogene 2000; 19: 2607-11.
22. Garcia R, Yu C-L, Hudnall A, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Diff 1997; 8: 1267-1276.
23. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379: 645-648.
24. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/Signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63: 1270-1279.
25. Sudbeck EA, Liu X-P, Krishna Narla R, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999; 5: 1569-1582.
26. Ber-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 2000; 60: 3127-3131.
27. Levis M, Allebach J, Tse K-F, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
28. Mohapatra S, Chu B, Wei S, et al. Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res 2003; 63: 8523-8530.
29. Li L, Hooi D, Chhabra SR, Pritchard D, Shaw PE. Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3. Oncogene 2004; 23: 4894-4902.
30. Songyang Z, Shoelson SE, Chaudburi M, et al. SH2 domains recognize specific phosphopeptide sequences. Cell 1993; 72: 767-778.
31. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal tranducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004; 3: 261-269.
32. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004; 2: 170-182.
33. Jing N, Y. I, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: A new class of signal transducer and activator of transcription 3 inhibitors that suppress growth of prostate and breast tumors through induction of apoptosis. Cancer Res 2004; 64: 6603-6609.
34. Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood 2003; 102: 3016-24.
35. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofen M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Res 2004; 3: 1183-1191.
36. Wemmer DE. Designed sequence-specific minor groove ligands. Annu Rev Biophys Biomol Struct 2000; 29:439-61.
37. Trauger JW, Baird EE, Dervan PB. Recognition of DNA by designed ligands at subnanomolar concentrations. Nature 1996; 382: 559-61.
38. Janssen S, Cuvier O, Muller M, Laemmli UK. Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster. Cell 2000; 6: 1013-1024.
39. Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921-924.
40. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924-928.
41. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signaling. Nature 1997; 387: 917-921.
42. Jackson PK. A new RING for SUMO: wrestling transcription responses into nuclear bodies with PIAS family E3 SUMO ligases. Genes Dev 2001;15: 3053-3058.
43. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated STAT3 in human tumors. Cancer Res 2005; in press.
44. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
45. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003; 101: 2784-8.
46. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001; 6 Suppl 5,8-14;8-14.
47. Kim HY, Park EJ, Joe EH, Jou I. Curcumin suppresses Janus kinase -STAT inflammatory signaling through activation of Sre homology 2 domain-containing tyrosine phosphate 2 in brain microglia, J Immunol 2003; 171: 6072-9.
48. Niu G, Shain KH, Huang M, et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res 2001; 61:3276-80.
49. Frank DA, Mahajan S, Ritz J, Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Med 1999; 5:444-447.
50. Liu W, Oseroff AR, Baumann H. Photodynamic therapy causes cross-linking of signal transducer and activator of transcription proteins and attenuation of interleukin-6 cytokin responsiveness in epithelial cells. Cancer Res 2004l; 64: 6579-6587.
51. Watson CJ, Miller WR. Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br J Cancer 1995; 71: 840-844.
52. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2002; 2: 381-392.
53. Groner B, Hennighausen L. Linear and cooperative signaling: roles for that proteins in the regulation of cell survival and apoptosis in the mammary epitheliu. Breast Cancer Res 2000; 2: 149-53.
54. Battle TE, Wierda WG, Rassenti LZ, et al. In vivo activation of STAT1 following CD154 gene therapy fo chronic lympocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res 2003; 9:2166-72.
55. Friedberg JW, Dong DA, Li S, et al. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. Leukemia Res 2004; 28: 139-147.
56. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronis Myeloid Leukemia. N Engl J Med 2001; 344: 1031-7.
57. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-26.
58. Burstein HJ, Kuter I, Campos SM, et al. Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cander. J Clin Oncol 2001; 19: 2722-30.
59. Sordella R, Bel DW, Haber DA, Settleman J, Gefitnib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways, Science 2004; 305: 1163-7.